SP-005

SP-005 is a small molecule pharmaceutical candidate developed by Sunny Pharmtech for the treatment of ulcerative colitis. It is formulated as an oral, sustained-release tablet designed to provide controlled delivery of the active ingredient to the gastrointestinal tract. Sunny Pharmtech, a specialty pharmaceutical company and Contract Development and Manufacturing Organization (CDMO), focuses on high-potency APIs and complex drug delivery technologies. According to the company's pipeline, SP-005 is currently in the pilot batch stage of development, which involves manufacturing process optimization and scale-up in preparation for further regulatory studies, such as bioequivalence testing. The product is part of Sunny Pharmtech's portfolio of value-added generics and specialty formulations, intended to manage inflammation associated with ulcerative colitis through targeted or prolonged therapeutic release.